Why the study?
Does lentiviral vector-based gene therapy in HIV+ subjects result in abnormal expansions of cells due to vector-mediated insertional activation of proto-oncogenes?
Population
3 HIV+ individuals receiving autologous infusions of gene-modified CD4+ T cells
Comparison
Lentiviral vector-based gene therapy targeting… vs Ex vivo vector-transduced CD4+ cell products
Design
Case_series
Follow-up
several times after infusion
Authors
Loading...
No insertional oncogenesis seen in this case; hypothesis-generating for lentiviral vector safety in HIV gene therapy, larger studies needed.
Does lentiviral vector-based gene therapy in HIV+ subjects result in abnormal expansions of cells due to vector-mediated insertional activation of proto-oncogenes?
Longitudinal analysis of lentiviral vector integration sites in HIV+ patients receiving gene-modified CD4+ T cells showed no evidence of insertional oncogenesis.
Wang et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: